Houston software development firm Axon is planning its Texas expansion thanks to its recent acquisition. Photo courtesy of Axon

For Owen D. Goode, Houstonians have a propensity for never being satisfied — and that's been extremely advantageous for his business.

“There’s this feeling in Houston of not being finished yet that I love,” says Goode. “Nobody is every fully satisfied in the best possible way. Nobody is sitting back and saying, ‘This is the best we could have done.’”

Goode, formerly the CEO of Axon, comes from an aviation background that includes operating as both pilot and mechanic. He now uses those skillsets in a very different world—helping to lead a company that focuses on system transformation. Axon, which was founded in 2017 was a boutique software firm focused on cloud engineering and data engineering.

This January, a larger company, Zaelot, led by CEO Jeff Lombard, acquired Axon. Zaelot is a global, software firm with a presence in 14 countries, mostly focused in the United States, Uruguay, and Iceland.

“Together we have a strong suite of offerings across a wide variety of domains including full-stack development, cloud/data engineering, design, staff augmentation, project management, and software architecture. We also have experience in multiple domains, including health care, aviation, defense, finance, and startups,” says Goode.

To the layman, this sounds impressive—and complicated—but what does Zaelot, actually do? Asked to explain at a kindergarten level, Goode says, “We take old code and make it less bad.”

With the motto, “Solve Today, Build Tomorrow,” Goode has worked with companies such as a major international airline to clean up its back end. Using a real estate analogy, Goode says that he and his team transform brownfield development environments (“a half-finished building that’s messy and there’s sewage everywhere”) into greenfield ones. It’s essentially a fresh start for sites that have become muddled over years of neglect.

“Health care is notoriously bad for that,” Goode says, though he is unable to disclose specific past or present clients.

Thanks to the merger with Zaelot, Goode and his team are now poised for rapid growth. Becoming part of a 100-person multinational company has now unlocked capital that Axon had never seen before. Goode promises rapid expansion in Texas, beginning in Houston in the next six months to a year. The executive—now Zaelot’s executive vice president—is already a well-known face on the Houston scene, where he regularly attends Cup of Joey and other Houston community events, such as CodeLaunch.

That growth includes gaining office space and expanding his staff in Space City.

“Zaelot's claim to fame is an extreme focus on employee satisfaction, with a 94 percent retention rate,” he says.

It’s his goal to keep those numbers up by serving the people who work for and with the company and treating them as human beings with families, not interchangeable parts. Next on the horizon, Goode says he and his team will be hiring sales and technical account management positions.

Though Zaelot’s staff is distributed around the world, Goode says Houston will always be home base for him. “It’s a literal launchpad that we’re continuing to grow off of,” he says. “I’m a big believer in Texas in general. And I’m just excited to see what happens.”

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.